Skip to Content
Merck
CN
  • Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2013-09-13)
Benjamin Kolisnyk, Mohammed A Al-Onaizi, Pedro H F Hirata, Monica S Guzman, Simona Nikolova, Shahar Barbash, Hermona Soreq, Robert Bartha, Marco A M Prado, Vania F Prado
ABSTRACT

One of the key brain regions in cognitive processing and executive function is the prefrontal cortex (PFC), which receives cholinergic input from basal forebrain cholinergic neurons. We evaluated the contribution of synaptically released acetylcholine (ACh) to executive function by genetically targeting the vesicular acetylcholine transporter (VAChT) in the mouse forebrain. Executive function was assessed using a pairwise visual discrimination paradigm and the 5-choice serial reaction time task (5-CSRT). In the pairwise test, VAChT-deficient mice were able to learn, but were impaired in reversal learning, suggesting that these mice present cognitive inflexibility. Interestingly, VAChT-targeted mice took longer to reach criteria in the 5-CSRT. Although their performance was indistinguishable from that of control mice during low attentional demand, increased attentional demand revealed striking deficits in VAChT-deleted mice. Galantamine, a cholinesterase inhibitor used in Alzheimer's disease, significantly improved the performance of control mice, but not of VAChT-deficient mice on the 5-CSRT. In vivo magnetic resonance spectroscopy showed altered levels of two neurochemical markers of neuronal function, taurine and lactate, suggesting altered PFC metabolism in VAChT-deficient mice. The PFC of these mice displayed a drastic reduction in the splicing factor heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2/B1), whose cholinergic-mediated reduction was previously demonstrated in Alzheimer's disease. Consequently, several key hnRNPA2/B1 target transcripts involved in neuronal function present changes in alternative splicing in VAChT-deficient mice, including pyruvate kinase M, a key enzyme involved in lactate metabolism. We propose that VAChT-targeted mice can be used to model and to dissect the neurochemical basis of executive abnormalities.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Synaptophysin antibody produced in mouse, clone SVP-38, ascites fluid
Sigma-Aldrich
N-Acetyl-L-aspartic acid, ≥99.0% (T)
Sigma-Aldrich
Taurine, ≥98%, FG
SAFC
Taurine
Sigma-Aldrich
Choline chloride, ≥99%
Supelco
Taurine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Choline chloride, ≥98%
Sigma-Aldrich
Choline chloride, BioUltra, ≥99.0% (AT)
Supelco
Choline chloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Choline chloride, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Sigma-Aldrich
Taurine, suitable for cell culture, meets USP testing specifications
Sigma-Aldrich
Taurine, BioUltra, ≥99.5% (T)
Sigma-Aldrich
Taurine, ≥99%
Sigma-Aldrich
Choline chloride, Vetec, reagent grade, ≥98%